Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPR206 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SPR206 | EXPERIMENTAL | SPR206 100mg single-dose IV infused over 1 hour |
| Name | Type | Description |
|---|---|---|
| SPR206 | DRUG | SPR206 100 mg single-dose IV infused over 1 hour |
Key Inclusion Criteria: * BMI ≥ 18.5 and ≤ 39.9 (kg/m2) and weight between 50.0 and 130.0 kg (inclusive) * Medically healthy without clinically significant abnormalities (Healthy Volunteers) or medically stable without clinically significant acute or chronic illness (Subjects with varying degrees o...
SPR206 is an investigational small molecule developed by Spero Therapeutics, Inc. (ticker SPRO). It has been studied in a Phase 1 clinical trial in subjects with varying degrees of renal function, including renal impairment. It is not an approved medicine and remains in clinical development.
SPR206 has been evaluated for use in renal impairment, with a Phase 1 study examining its pharmacokinetics and safety in subjects with various degrees of renal function. The program is at the Phase 1 stage, so SPR206 is investigational and has no approved indication.
SPR206 is developed by Spero Therapeutics, Inc., which trades under the ticker SPRO. The company sponsored the Phase 1 study of SPR206 in subjects with various degrees of renal function.
SPR206 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. SPR206 is investigational and has not been approved by the FDA for any indication.
SPR206 has been studied in one completed Phase 1 trial, NCT04865393, titled a Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function. It enrolled 37 participants in New Zealand and was an uncontrolled study without randomization or blinding.